Biomarker enrichment strategies: matching trial design to biomarker credentials (Q38166566)

30 August 2017

Biomarker enrichment strategies: matching trial design to biomarker credentials (English)

1 reference

30 August 2017

0 references

1

Boris Freidlin

1 reference

30 August 2017

Edward L Korn

2

1 reference

30 August 2017

language of work or name

English

0 references

publication date

26 November 2013

1 reference

Nature Reviews Clinical Oncology

30 August 2017

1 reference

30 August 2017

11

1 reference

30 August 2017

2

1 reference

30 August 2017

81-90

1 reference

https://scigraph.springernature.com/pub.10.1038/nrclinonc.2013.218

30 August 2017

0 references

cites work

Enrichment of clinical study populations

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Bridging the gap: moving predictive and prognostic assays from research to clinical use

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Use of archived specimens in evaluation of prognostic and predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Statistical and practical considerations for clinical evaluation of predictive biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Evaluating the efficiency of targeted designs for randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

HER2 status and benefit from adjuvant trastuzumab in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Randomized clinical trials with biomarkers: design issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Testing in a Prespecified Subgroup and the Intent-to-Treat Population

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

A two-stage Bayesian design for co-development of new drugs and companion diagnostics.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Marker Sequential Test (MaST) design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Phase III clinical trials that integrate treatment and biomarker evaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

The use of genomics in clinical trial design

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

A threshold sample-enrichment approach in a clinical trial with heterogeneous subpopulations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Design issues of randomized phase II trials and a proposal for phase II screening trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Promoter CpG island hypermethylation of the DNA repair enzyme MGMT predicts clinical response to dacarbazine in a phase II study for metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Randomized phase II study of ixabepilone or paclitaxel plus carboplatin in patients with non-small-cell lung cancer prospectively stratified by beta-3 tubulin status.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

An adaptive Simon Two-Stage Design for Phase 2 studies of targeted therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Randomized phase II trial designs with biomarkers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Targeting adjuvant chemotherapy: a good idea that needs to be proven!

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

TAILORx: trial assigning individualized options for treatment (Rx)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

Design of a phase III clinical trial with prospective biomarker validation: SWOG S0819

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2013.218

10.1038/NRCLINONC.2013.218

31 March 2020

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1021643934

0 references

Fatcat ID

release_25uelxy6afh2pfrmgrjzzjt6si

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/25uelxy6afh2pfrmgrjzzjt6si

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference